Hugl-1 inhibits glioma cell growth in intracranial model

Abstract

Drosophila lethal (2) giant larvae (lgl) has been reported as a tumor suppressor and could regulate the Drosophila hippo signaling. Human giant larvae-1(Hugl-1), one human homologue of Drosophila lgl, also has been reported to be involved in the development of some human cancers. However, whether Hugl-1 is associated with the pathogenesis of malignant gliomas remains poorly understood. In the present work, we examined the effect of Hugl-1 on glioma cell growth both in vitro and in vivo. Firstly, we found that Hugl-1 protein levels decreased in the human glioma tissues, suggesting that Hugl-1 is involved in glioma progression. Unfortunately, either stably or transiently over-expressing Hugl-1 did not affect glioma cell proliferation in vitro. In addition, Hugl-1 over-expression did not regulate hippo signaling pathway. Interestingly, over-expression of Hugl-1 not only inhibited gliomagenesis but also markedly inhibited cell proliferation and promoted the apoptosis of U251 cells in an orthotopic model of nude mice. Taken together, this study provides the evidence that Hugl-1 inhibits glioma cell growth in intracranial model of nude mice, suggesting that Hugl-1 might be a potential tumor target for glioma therapy.

β-catenin-mediated YAP signaling promotes human glioma growth

“…Band densities were quantified by ImageJ Software (Wayne Rasband, National Institutes of Health, MD). The relative amount of proteins was determined by normalizing the densitometry value of interest to that of the loading control [ 22 ].…”

“…Intracranial model of glioma in nude mice was performed according to our previous study [ 22 ]. All the in vivo experiments were carried out with ethical committee approval and met the standards required by the guidelines of Xuzhou Medical University.…”

Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway

“…Lenti-RASD1 or Lenti-Vector U87 cells (1 × 10 6 ) were stereotactically injected into the right striatum of nude mice as described in our previous studies 30, 31 . The mice were sacrificed when cachexia occurred in the tumor growth assay or at two weeks after glioma cell transplantation for the tumor invasion assay.…”

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

“…Male athymic BALB/c nude mice aged 5 to 6 weeks were obtained from the Experimental Animal Center of Xuzhou Medical College. Firefly luciferase-labeled U87 cells (5 × 10 5 cells per mouse) were intracranially injected into the right striatum of nude mice using a small animal stereotactic apparatus as described in our previous report [ 31 , 32 ]. Once the presence of a tumor was confirmed by imaging system, the tumor-bearing mice were randomly divided into one of the following three treatment groups ( n = 8 per group): S109 at 20 mg/kg, S109 at 50 mg/kg, and vehicle.…”